These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9005412)

  • 21. [Body weight gain after radioiodine therapy in hyperthyroidism].
    Scheidhauer K; Odatzidu L; Kiencke P; Schicha H
    Nuklearmedizin; 2002 Feb; 41(1):47-51. PubMed ID: 11917349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
    Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
    Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paradoxical effect of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy].
    Dunkelmann S; Rudolph F; Prillwitz A; Groth P; Schümichen C
    Nuklearmedizin; 1998 Jan; 37(1):23-9. PubMed ID: 9467166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radioiodine therapy of funcitonal autonomy using the functional autonomous volume].
    Seeger T; Emrich D; Sandrock D
    Nuklearmedizin; 1995 Aug; 34(4):135-40. PubMed ID: 7675642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study.
    Peters H; Fischer C; Bogner U; Reiners C; Schleusener H
    Eur J Clin Invest; 1996 Jan; 26(1):59-63. PubMed ID: 8682157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The reactions of euthyroid and hyperthyroid glands to radioactive iodine.
    Friedman NB; Catz B
    Arch Pathol Lab Med; 1996 Jul; 120(7):660-1. PubMed ID: 8757471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
    Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
    Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Can radioactive iodine be used in the treatment of diffuse non-toxic goiter?].
    Nygaard B; Hegedüs L; Bennedbaek FN; Veje A; Faber JO; Hansen JE
    Ugeskr Laeger; 1998 Sep; 160(37):5349-52. PubMed ID: 9748860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
    Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine treatment of Basedow's disease: interference and influence factors, risk estimation.
    Reiners C
    Exp Clin Endocrinol; 1991 May; 97(2-3):275-85. PubMed ID: 1915645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of Basedow disease after radioiodine therapy for nodular goiter].
    Cseke B; Balázs C
    Orv Hetil; 2003 Nov; 144(47):2327-9. PubMed ID: 14725052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radiotherapy with 131J and 125J of Basedow's disease. Indications and results relative to the incidence of post-actinic hypothyroidism].
    Dradi C; Riceputi G; Biagioli R; Riva P
    Minerva Med; 1979 Jan; 70(2):135-41. PubMed ID: 581903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
    Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
    Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
    Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
    J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy-induced thyroid disorders.
    Jereczek-Fossa BA; Alterio D; Jassem J; Gibelli B; Tradati N; Orecchia R
    Cancer Treat Rev; 2004 Jun; 30(4):369-84. PubMed ID: 15145511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Graves' disease nd toxic nodular goiter--radioiodine therapy].
    Schicha H; Dietlein M
    Nuklearmedizin; 2002 Apr; 41(2):63-70. PubMed ID: 11989300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.